This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This TYROBP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 85-113 amino acids from the C-terminal region of human TYROBP.
TYROBP
Reactivity: Mouse
WB, FACS, ELISA, IF (cc), IF (p), IHC (p), IHC (fro)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
For FACS starting dilution is: 1:10~50
Restrictions
For Research Use only
Format
Liquid
Concentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TYROBP
(TYRO Protein tyrosine Kinase Binding Protein (TYROBP))
TYROBP antibody, DAP12 antibody, tyrpbp antibody, Karap antibody, KARAP antibody, PLOSL antibody, Ly83 antibody, dap12 antibody, TYRO protein tyrosine kinase binding protein antibody, Tyro protein tyrosine kinase binding protein antibody, TYROBP antibody, tyrobp antibody, Tyrobp antibody
Background
TYROBP encodes a transmembrane signaling polypeptide which contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The encoded protein may associate with the killer-cell inhibitory receptor (KIR) family of membrane glycoproteins and may act as an activating signal transduction element. This protein may bind zeta-chain (TCR) associated protein kinase 70 kDa (ZAP-70) and spleen tyrosine kinase (SYK) and play a role in signal transduction, bone modeling, brain myelination, and inflammation. Mutations within this gene have been associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as Nasu-Hakola disease. Its putative receptor, triggering receptor expressed on myeloid cells 2 (TREM2), also causes PLOSL.